Aerpio Pharmaceuticals, Inc. (ARPO) relating to its proposed merger with Aadi Bioscience, Inc. Under the terms of the agreement, ARPO shareholders are expected to own 14.7% of the combined company after the closing of the concurrent PIPE financing transaction.